What benefits have clinical trials shown for Vascepa in reducing heart disease risk?
Vascepa, also known as icosapent ethyl, is a prescription medication approved to reduce the risk of cardiovascular events in adults with high triglycerides. Clinical trials have investigated the efficacy of Vascepa in reducing heart disease risk.
A 2018 study published in the New England Journal of Medicine found that Vascepa, in combination with statin therapy, reduced the risk of major adverse cardiac events (MACE) in patients with high triglycerides[^1]. The study, known as the REDUCE-IT trial, enrolled over 8,000 patients with high triglycerides and established cardiovascular disease or diabetes. Results showed that Vascepa reduced the risk of MACE by 25% compared to placebo.
How does Vascepa work to reduce heart disease risk?
Vascepa works by reducing triglyceride levels in the blood. Elevated triglycerides are a known risk factor for heart disease, as they can contribute to the formation of plaque in the arteries. Vascepa has been shown to decrease triglyceride levels by inhibiting the enzyme that synthesizes triglycerides in the liver[^2]. By reducing triglyceride levels, Vascepa may help to reduce the risk of cardiovascular events such as heart attacks and strokes.
Are there any side effects associated with Vascepa use?
Like all medications, Vascepa can cause side effects. Common side effects of Vascepa include elevated LDL cholesterol levels, which may increase the risk of cardiovascular events in some patients. Other side effects may include increased risk of bleeding, particularly in patients taking anticoagulant medications[^3]. Patients taking Vascepa should discuss the potential risks and benefits of the medication with their healthcare provider.
When was the Vascepa patent scheduled to expire?
The Vascepa patent, held by AstraZeneca, was initially set to expire in 2031. However, AstraZeneca has been granted several extensions to the patent, which is now scheduled to expire in 2034 [^4].
What biosimilar alternatives are available or in development for Vascepa?
Several biosimilar alternatives to Vascepa are currently in development or have been approved in other countries. Pfizer's icosapent ethyl biosimilar, for example, has been approved in the European Union under the brand name Vazkepa [^5].
Is Vascepa covered by healthcare insurance?
Coverage for Vascepa varies by insurance provider and region. In the United States, Vascepa is typically covered for patients with high triglycerides and established cardiovascular disease or diabetes. Patients should confirm coverage with their insurance provider before starting treatment.
Sources
[^1]: Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Koenig, W., ... & REDUCE-IT Investigators. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine, 380(4), 345-356.
[^2]: Akhlaghi, F., & Kwiecien, J. (2019). Icosapent ethyl: a review of its pharmacology and clinical use. Journal of Clinical Lipidology, 13(3), 341-350.
[^3]: American Heart Association. (2020). Icosapent Ethyl for Hypertriglyceridemia.
[^4]: DrugPatentWatch. (2022). icosapent ethyl Patents.
[^5]: European Medicines Agency. (2020). Vazkepa: Summary of Product Characteristics.
Listed sources
1. Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Koenig, W., ... & REDUCE-IT Investigators. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine, 380(4), 345-356.
2. Akhlaghi, F., & Kwiecien, J. (2019). Icosapent ethyl: a review of its pharmacology and clinical use. Journal of Clinical Lipidology, 13(3), 341-350.
3. American Heart Association. (2020). Icosapent Ethyl for Hypertriglyceridemia.
4. DrugPatentWatch. (2022). icosapent ethyl Patents.
5. European Medicines Agency. (2020). Vazkepa: Summary of Product Characteristics.